Trial Profile

A 52-Week, Multicenter, Phase 1 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LX 1001 (Primary)
Indications Alzheimer's disease; Mild cognitive impairment
Focus Adverse reactions
Sponsors LEXEO Therapeutics

Most Recent Events

22 Nov 2024 Status changed from active, no longer recruiting to completed.
30 Oct 2024 According to a Lexeo Therapeutics media release, Company has initiated engagement with FDA on these data and expects to provide an update on regulatory interactions and further LX1001 development plans in 2025.
30 Oct 2024 According to a Lexeo Therapeutics media release, Dr. Kim Johnson is the principal investigator of the trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com